^
Association details:
| Biomarker: | STK11 mutation + KEAP1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and the influence of the NLR in NSCLC patients treated with immunotherapy.
Published date:
05/19/2021
Excerpt:
We conducted a retrospective study including all consenting patients with NSCLC treated with ICIs...The presence of STK11 and/or KEAP1 mutations was associated with a negative impact on survival when compared with wild-type (median OS 7.4 vs 20.4 months, p = 0.001)....The STK11 and KEAP1 mutations are significant adverse predictors of ICI therapy benefit.
DOI:
10.1200/JCO.2021.39.15_suppl.e21010
